Cisplatin

Generic Name: Cisplatin

Brand Names: Platinol

Drug Type: Small Molecule

Chemical Formula: Cl_₂H_₆N_₂Pt

CAS Number: 15663-27-1

Unique Ingredient Identifier: Q20Q21Q62J

Background: Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication: For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions: Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer

Associated Therapies: -

Clinical Trials

Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

Phase 3

Active, not recruiting

Conditions: Endometrial Neoplasms

Interventions: Biological: Pembrolizumab
Drug: Carboplatin
Drug: Placebo for pembrolizumab
Drug: Paclitaxel
Drug: Docetaxel
Drug: Cisplatin
Radiation: External Beam Radiotherapy (EBRT)
Drug: Cisplatin (as radiosensitizer)
Radiation: Brachytherapy

First Posted Date: 2020-11-18

Last Posted Date: 2024-11-19

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 990

Registration Number: NCT04634877

Locations: 🇨🇦
Kingston Health Sciences Centre ( Site 3003), Kingston, Ontario, Canada
🇺🇸
University of South Alabama, Mitchell Cancer Institute ( Site 3058), Mobile, Alabama, United States
🇺🇸
WK Physicians Network/Gynecologic Oncology Associates ( Site 3047), Shreveport, Louisiana, United States

and more 228 locations

Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC

Phase 2

Recruiting

Conditions: Bladder Cancer

Interventions: Drug: Recombinant intravesical BCG (Bacillus Calmette-Guérin VPM1002BC)
Drug: Atezolizumab
Drug: Cisplatin
Drug: Gemcitabine

First Posted Date: 2020-11-16

Last Posted Date: 2024-03-12

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 46

Registration Number: NCT04630730

Locations: 🇨🇭
Kantonsspital Baden, Baden, Switzerland
🇨🇭
Klinik Hirslanden - Onkozentrum Hirslanden, Zürich, Switzerland
🇨🇭
UniversitaetsSpital Zuerich, Zurich, Switzerland

and more 7 locations

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

Phase 2

Recruiting

Conditions: Renal Pelvis and Ureter Urothelial Carcinoma

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Drug: Cisplatin
Procedure: Computed Tomography
Drug: Doxorubicin Hydrochloride
Drug: Gemcitabine Hydrochloride
Biological: Durvalumab
Procedure: Magnetic Resonance Imaging
Drug: Methotrexate
Biological: Pegfilgrastim
Procedure: Therapeutic Conventional Surgery
Drug: Vinblastine Sulfate

First Posted Date: 2020-11-16

Last Posted Date: 2024-12-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 249

Registration Number: NCT04628767

Locations: 🇺🇸
Advocate South Suburban Hospital, Hazel Crest, Illinois, United States
🇺🇸
Loyola Medicine Homer Glen, Homer Glen, Illinois, United States
🇺🇸
Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States

and more 244 locations

A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Phase 2

Active, not recruiting

Conditions: Non-small Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer
Metastatic Non-small Cell Lung Cancer

Interventions: Biological: Nivolumab
Biological: Relatlimab
Drug: Carboplatin
Drug: Paclitaxel
Drug: Cisplatin
Drug: Pemetrexed
Drug: Nab-Paclitaxel

First Posted Date: 2020-11-10

Last Posted Date: 2024-12-20

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 468

Registration Number: NCT04623775

Locations: 🇺🇸
Local Institution - 0147, Pittsburgh, Pennsylvania, United States
🇧🇪
Local Institution - 0131, Ghent, Belgium
🇧🇪
Local Institution - 0125, Roeselare, Belgium

and more 122 locations

Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer

Phase 2

Completed

Conditions: Carcinoma, Small Cell Lung

Interventions: Drug: Atezolizumab
Drug: Cisplatin
Drug: Carboplatin
Drug: Etoposide
Radiation: Thoracic radiation therapy (TRT)

First Posted Date: 2020-11-09

Last Posted Date: 2024-07-29

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 56

Registration Number: NCT04622228

Locations: 🇨🇳
Cancer Hospital , Chinese Academy of Medical, Beijing City, China
🇨🇳
West China Hospital - Sichuan University, Chengdu City, China
🇨🇳
Second Affiliated Hospital of Third Military Medical University, Chongqing, China

and more 5 locations

A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer

Phase 2

Active, not recruiting

Conditions: Non-small Cell Lung Cancer (NSCLC)

Interventions: Drug: Tiragolumab
Drug: Atezolizumab
Drug: Pemetrexed
Drug: Tiragolumab Matching Placebo
Drug: Carboplatin
Drug: Cisplatin
Drug: Pembrolizumab

First Posted Date: 2020-11-06

Last Posted Date: 2024-12-11

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 542

Registration Number: NCT04619797

Locations: 🇧🇪
Vitaz, Sint Niklaas, Belgium
🇫🇷
CHU Strasbourg - Nouvel Hopital Civil, Strasbourg, France
🇯🇵
The Cancer Institute Hospital of JFCR, Tokyo, Japan

and more 137 locations

A Study Evaluating the Efficacy and Safety of Adjuvant Platinum-Doublet Chemotherapy, With or Without Atezolizumab, in Patients Who Are ctDNA Positive After Complete Surgical Resection of Stage IB to Select IIIB Non-Small Cell Lung Cancer

Phase 2

Withdrawn

Conditions: Carcinoma, Non-Small Cell Lung

Interventions: Drug: Placebo
Drug: Atezolizumab
Drug: Carboplatin
Drug: Cisplatin
Drug: Pemetrexed
Drug: Gemcitabine
Drug: Paclitaxel

First Posted Date: 2020-11-02

Last Posted Date: 2021-06-16

Lead Sponsor: Hoffmann-La Roche

Registration Number: NCT04611776

Trial of BMX-001 or Placebo in Head and Neck Cancer Patients

Phase 2

Withdrawn

Conditions: Head and Neck Cancer

Interventions: Drug: BMX-001
Radiation: Radiation Therapy
Other: Placebo
Drug: Cisplatin

First Posted Date: 2020-10-29

Last Posted Date: 2021-10-11

Lead Sponsor: BioMimetix JV, LLC

Registration Number: NCT04607642

Chemo-embolization for Head and Neck Cancer

Phase 2

Not yet recruiting

Conditions: SCCHN
Squamous Cell Carcinoma

Interventions: Drug: Cisplatin

First Posted Date: 2020-10-22

Last Posted Date: 2024-04-25

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 48

Registration Number: NCT04595981

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

Phase 3

Active, not recruiting

Conditions: HER2-negative Breast Cancer
Triple Negative Breast Cancer

Interventions: Drug: Capecitabine
Drug: Sacituzumab govitecan
Drug: Carboplatin
Drug: Cisplatin

First Posted Date: 2020-10-20

Last Posted Date: 2024-11-22

Lead Sponsor: German Breast Group

Target Recruit Count: 1332

Registration Number: NCT04595565

Locations: 🇪🇸
Hospital Universitario de Fuenlabrada, Fuenlabrada, Spain
🇪🇸
Hospital Galdakao-Usansolo, Galdakao, Spain
🇪🇸
Hospital Universitario Clinico San Cecilio, Granada, Spain

and more 157 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy